Volumetric Biotechnologies has announced its moving its HQ to the East End Maker Hub. Image courtesy of East End Maker Hub

The East End Maker Hub has landed perhaps its most intriguing tenant thus far — a Houston startup that makes 3D-printed human organs.

Volumetric Biotechnologies Inc. has leased 11,200 square feet at the East End Maker Hub to serve as its headquarters and manufacturing center. Jordan Miller, co-founder of Volumetric, says one of the benefits of being located at the hub will be access to a cleanroom operated by Alchemy Industrial, a 3D manufacturer of medical devices. Earlier this year, Houston-based Alchemy leased more than 5,400 square feet at the East End hub.

Volumetric will occupy space in the first phase of the 307,000-square-foot project East End Maker Hub. That phase of the $37 million project is set to open soon. The startup's current 5,000-square-foot headquarters is at 7505 Fannin St., near the Woman's Hospital of Texas and south of the Texas Medical Center.

Miller says Volumetric's new home will help it "maintain and accelerate our already breakneck progress." Volumetric's 12 biological, chemical, mechanical, and electrical engineers focus on producing human organs and tissues like the liver, kidney, pancreas, lung, and heart using a mix of medical-grade plastics and human cells.

"We're straining to scale our company as fast as our team is inventing and progressing our technologies. It's an absolutely wonderful problem to have," Miller says.

Volumetric hopes to commercialize its 3D-printed organs in 2021. Founded in 2018, Volumetric is a privately held spin-out of Rice University's Department of Bioengineering. It has received $1.8 million in funding, according to Crunchbase. Investors include Silicon Valley-based Sand Hill Angels, and the Springfield, Virginia-based Methuselah Foundation and Methuselah Fund.

Local Realtor Mike Pittman, a development associate with Pearland-based project partner Urban Partnerships Community Development Corp., recruited Volumetric to the hub. He says he's also working with a distillery, a coffee roaster, and a medical gown manufacturer on leasing space there.

The first phase of the East End Maker Hub is set to open soon. Image courtesy of East End Maker Hub

Once the East End Maker Hub opens, Houston's East End District will be home to the largest maker hub in Texas and one of the largest such facilities in the U.S. Being built in three phases on a 21-acre site at 6501 Navigation Blvd., the East End Maker Hub aims to create an environment that gives members of the community access to trade skills and career opportunities, and to provide businesses a place for innovation and manufacturing. The hub's second and third phases are on track to be finished in 2021.

The soon-to-open first phase will feature "white box" suites, ranging in size from 420 square feet to 20,000 square feet, that cater to three sectors:

  • Innovation (robotics, 3D printing, and R&D)
  • Crafting (ceramics, fine woodworking, and screen printing)
  • Light fabrication (food production).

Aside from Alchemy, tenants recently lined up for the hub include Houston-based Waste Management Inc., whose R&D team will occupy more than 3,500 square feet, and Houston-based construction technology company Rugged Robotics Inc., which is renting 1,700 square feet.

"We're not the place for software companies, but our innovation area is the place for hardware companies — those that are into drones, robotics, 3D printing," Pittman says.

The project's hardware innovation element could boost Houston's manufacturing economy, he says. A recent analysis by the Smartest Dollar website found that 7.5 percent of the Houston metro area's workforce is employed in manufacturing. From 1999 to 2019, the number of manufacturing jobs in Houston grew by just 1.9 percent.

So far, the nonprofit TXRX Labs makerspace is the hub's largest tenant, having signed a lease for 65,000 square feet in the first phase. TXRX Labs and Urban Partnerships Community Development teamed up to develop the hub. TXRX contributed $1.25 million in equity, and Urban Partnerships Community Development raised $35.75 million in capital.

Houston-based Stewart Builders is the general contractor for the East End Maker Hub, and Houston-based Method Architecture is the architect of record.

Aside from supplying room for businesses and nonprofits to grow, the hub seeks to provide training and jobs for local residents. Pittman says the hub — located within a tax-advantaged Opportunity Zone — encourages its tenants to hire people who live within a three-mile radius.

"You don't have to go and get a Ph.D. in nuclear science for these jobs to be able to attain really good wages for your family," he says.

Phases two and three of the hub are expected in 2021. Image courtesy of East End Maker Hub

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”